Ganfeborole

Phase 2Small molecule

UUniversity College, London

Ganfeborole is one of 93 small molecule programs targeting Tuberculosis, Pulmonary. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tuberculosis, PulmonaryNot yet recruiting

TuberculosisNot yet recruiting

ESSRecruiting

NACRecruiting

Tuberculosis, PulmonaryPhase 2

Not yet recruiting

TuberculosisPhase 1

Not yet recruiting

ESSPhase 2

Recruiting

NACPhase 2

Recruiting

Competition

Competitive Landscape

85 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Phase 3

17 2

Avelox

Bayer

Phase 3

12 3

Zyvox

Pfizer

Phase 3

10 4

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

24 5

Lamprene

Novartis

Phase 3

5 6

Sirturo

WWim Janssens

Phase 3

9 7

Levaquin

WWim Janssens

Phase 3

8 8

Deltyba

Otsuka

Phase 3

7 9

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Tuberculosis

NCT07784894

Q3 2027

Phase 2Recruiting

ESS

NCT06114628

Q4 2027

Phase 2Recruiting

NAC

NCT05807399

Phase 2Not yet recruiting

Tuberculosis, Pulmonary

NCT07773610

Clinical

Trials by Indication[1]

NAC1 trial

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

ESS1 trial

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting·UUniversity College, London·Phase 2·NCT06114628·2,500 enrolled

Tuberculosis1 trial

A Phase 1, Open-Label, Fixed Sequence, 1-Way Drug-Drug Interaction Study to Investigate the Repeat-Dose Pharmacokinetics of Microgynon, an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel, When Administered Alone and in Combination With Ganfeborole in Healthy Female Participants of Non-Childbearing Potential Aged 18-65 Years Old

Not yet recruiting· GSK logo

GSK·Phase 1·NCT07784894·28 enrolled

Tuberculosis, Pulmonary1 trial

A Phase 2, Randomised, Controlled, Multicentre Two-Part Trial Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis

Not yet recruiting·TTASK Applied Science·Phase 2·NCT07773610·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ganfeborole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ganfeborole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ganfeborole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity College, London

Ganfeborole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

NAC1 trial

ESS1 trial

Tuberculosis1 trial

Tuberculosis, Pulmonary1 trial

References

Drug Info

Quick Facts

Related News